(415) 353-9888 (appts)
(415) 353-9959 (fax)

Box 1705, UCSF; San Francisco, CA 94143-1705

additional websites:

UCSF Physician Referral Directory

Rutgers College, New Brunswick, New Jersey, BA, 1976, Biological Sciences
University of California San Francisco, MD, 1980, Medicine
University of California San Francisco, Internship, 1981, Internal Medicine
University of California, Davis, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1987, Hematology/Oncology

Melisko ME, Fox R, Venook A: Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol, 16(3): 177-83, 2004.

Venook A: Key research issues in the management of hepatocellular carcinoma. Cancer Chemother Pharmacol, (Suppl 1): S87-S90, 2004.

Whisenant J, Venook A: Regional therapy of liver metastases. Curr Treat Options Oncol, 5 (5): 427-37, 2004.

Venook A: Colorectal metastases to the liver: resection and medical therapy. The American J of Oncol Review, 3 (10): 36-43, 2004.

Venook A: Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. JNCCN, 2(2): S74- S84, 2004.

Alberts D, Muggia F, Carmichael J, Winer E, Jahanzeb M, Venook A, Skubitz K, Rivera E, Sparano J, Dibella N, Stewart S, Kavanagh J, Gabizon A: Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Semin Oncol, 31(6) Suppl 13: 53-90, 2004.

Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. The Oncologist, 10:250-261, 2005.

Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond J, Roberts JP: The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant, Apr; 5(4):795-804, 2005.

Mehta KR, Nakao K, Zuraek M, Ruan DT, Bergsland E, Venook AP, Moore, DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM: Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res, 11:1791-1797, 2005.

Venook, AP: Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 103/12:2435-2446, 2005.

Ko A, Hwang J, Venook A, Abbruzzese J, Bergsland E, Tempero M: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer, 93(2): 195-9, 2005.

Venook A, Blanke C, Niedzwiecki D, Lenz H-J, Taylor J, Hollis D, Sutherland S, Goldberg R: Cancer and leukemia group b/southwest oncology group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer, 5(4):292-4, 2005.

Ko A, Dito E, Schillinger B, Venook A, Bergsland E, Tempero M.: Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol, 24(3): 379-385, 2006.

Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R.: Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase I colorectal cancer trial. Cancer Gene Ther. 13(2): 169-181, 2006.

Rajpal S, Venook A: Targeted Therapy in Colorectal Cancer. Clin Adv in Hem & Oncol.4(2):124-132, 2006.

Venook A, Blanke C, Goldberg R, Reinke D, Sutherland S, Taylor J, McAllister P, Schilsky R.: Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer. Comm Oncol. 3(9): 1-6, 2006.

Benson AB, Bekaii-Saab T, Ben-Josef E, Blumgart L, Clary BMM, Curl, BM, Curley SA, Davila R, Earle CC, Ensminger WD, Gibbs JF, Laheru D, Langnas AN, Mulvihill SJ, Nemcek AA Jr, Posey JA, Sigurdson ER, Sinurdson ER, Sinanan M, Vauthey JN, Venook AP, Wagman LD, Yeatman TJ: National Comprehensive Cancer Network.: Hepatobiliary cancers. Clinical practice guidelines in oncology. J Natl Compr Cancr Netw. Sep 4(8):728-50, 2006.

Allegra A, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol N, Saltz L, Venook A, Yothers G, Sargent D: End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol. Aug 20 (25):3572-75, 2007.

Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, Satomura S, Schwartz ME: Clinical utility of AFP-L3% measurement in north American patients with hcv-related cirrhosis. Am J Gastroenterol. Oct: 102(10): 2196-205, 2007.

Choo SP, Venook AP: An alternative therapy for patients with hepatic impairment? Onkologie. Oct; 30(10):474-5, 2007.

Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP: Colon Cancer. J Natl Compr Canc Netw. Oct; 5(9): 884-925, 2007.

Engstrom PF, Arnoletti JP, Benson AB 3rd, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Fakih MG, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Ludwig KA, Martin EW Jr, Rao S, Saltz L, Shibata D, Skibber JM, Venook AP: Colon Cancer. J Natl Compr Canc Netw. Oct; 5(9): 884-925, 2007.

Posner MD, Niedzwiecki D, Venook AP, Hollis DR, Kindler HL, Martin EW, Schilsky RL, Goldberg RM: A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group b study 89903. Ann Surg Oncol. Nov 16, 2007.

O'Neil B, Venook AP: Hepatocellular carcinoma, the role of the North American GI steering committee hepatobiliary task force, and the advent of the effective drug therapy. Oncologist. Dec; 12: 1425-1432, 2007.

Ko AH, Dito E, Schillinger B, Venook AP Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. Feb; 26(1):47-52, 2008.

Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. Jan 7(1):44-7, 2008.

Choo, SP, Venook AP. Hepatic artery infusion in the treatment of colorectal cancer metastases. Curr Col CA Reports. April (4) 2, 106-113, 2008.

Choo, SP, Venook AP. Responding to the rising incidence of hepatocellular carcinoma with targeted therapy (editorial). Gastroin Ca Res. March/April (2) 2, 96-7, 2008.

Figlin RA, Brown E, Armstrong A, Akerley W, Berson AB, Burstein HJ, Ettinger DS, Febbbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task force report: mTOR inhibition in solid tumors. J of the NCCN. Sept, 6 (5), 2008.

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. Oct;26(5):463-71, 2008.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. Oct; 37(3):269-74, 2008.

Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: seoaratubg the hype from the hope. J Clin Oncol. Dec 20;26(36):5845-8, 2008.

Sterling RK, Jeffers L, Gordon F, Venook AP, Reddy KR, Satomura S, Kanke F, Schwartz ME, Sherman M. Utility of lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination , as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol. Jan; 7(1): 104-13, 2009.

6/9/09